The innate immune system in Alzheimer's disease

International Journal of Cell Biology

Volumn , Issue , 2013, Pages

  Boutajangout, Allal ^a,b   Wisniewski, Thomas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; CPG OLIGODEOXYNUCLEOTIDE; PATTERN RECOGNITION RECEPTOR; PROTEIN; PROTEIN TREM 2; REACTIVE OXYGEN METABOLITE; TAU PROTEIN; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 11; TOLL LIKE RECEPTOR 12; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; AMYLOID PLAQUE; COGNITION; CYTOKINE PRODUCTION; DENDRITIC CELL; FRONTOTEMPORAL DEMENTIA; GENETIC RISK; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; INNATE IMMUNITY; MACROPHAGE; MACROPHAGE ACTIVATION; MICROGLIA; NEUROFIBRILLARY TANGLE; OSTEOCLAST; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RNA INTERFERENCE; SENILE PLAQUE; VASCULAR AMYLOIDOSIS;

EID: 84886684931     PISSN: 16878876     EISSN: 16878884     Source Type: Journal    
DOI: 10.1155/2013/576383     Document Type: Review

References (96)

1. Prince M., Bryce R., Ferri C., World Alzheimer Report 2011. Alzheimer's Disease International 2011
2. Bertram L., Tanzi R. E., The genetics of Alzheimer's disease. Progress in Molecular Biology and Translational Science 2012 107 79 100 2-s2.0-84859584667 10.1016/B978-0-12-385883-2.00008-4
3. Ridge P. G., Ebbert M. T., Kauwe J. S., Genetics of Alzheimer's disease. BioMed Research International 2013 2013 13 254954 10.1155/2013/254954
4. Potter H., Wisniewski T., Apolipoprotein E: essential catalyst of the Alzheimer amyloid cascade. International Journal of Alzheimer's Disease 2012 2012 9 489428 10.1155/2012/489428
5. Verghese P. B., Castellano J. M., Holtzman D. M., Apolipoprotein E in Alzheimer's disease and other neurological disorders. The Lancet Neurology 2011 10 3 241 252 2-s2.0-79951713725 10.1016/S1474-4422(10)70325-2
6. Barnes D. E., Yaffe K., The projected effect of risk factor reduction on Alzheimer's disease prevalence. The Lancet Neurology 2011 10 9 819 828 2-s2.0-80051669619 10.1016/S1474-4422(11)70072-2
7. Guerreiro R., Wojtas A., Bras J., TREM2 variants in Alzheimer's disease. The New England Journal of Medicine 2013 368 2 117 127 10.1056/NEJMoa1211851
8. Neumann H., Daly M. J., Variant TREM2 as risk factor for Alzheimer's disease. The New England Journal of Medicine 2013 368 2 182 184 10.1056/NEJMe1213157
9. Jonsson T., Stefansson H., Steinberg S., Variant of TREM2 associated with the risk of Alzheimer's disease. The New England Journal of Medicine 2013 368 2 107 116 10.1056/NEJMoa1211103
10. Bouchon A., Hernández-Munain C., Cella M., Colonna M., A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. The Journal of Experimental Medicine 2001 194 8 1111 1122 2-s2.0-0035887503 10.1084/jem.194.8.1111 (Pubitemid 32995781)
11. N'Diaye E.-N., Branda C. S., Branda S. S., Nevarez L., Colonna M., Lowell C., Hamerman J. A., Seaman W. E., TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria. The Journal of Cell Biology 2009 184 2 215 223 2-s2.0-60849109512 10.1083/jcb.200808080
12. Arroyo D. S., Soria J. A., Gaviglio E. A., Rodriguez-Galan M. C., Iribarren P., Toll-like receptors are key players in neurodegeneration. International Immunopharmacology 2011 11 10 1415 1421 2-s2.0-80053289163 10.1016/j.intimp.2011.05.006
13. Hanke M. L., Kielian T., Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clinical Science 2011 121 9 367 387 2-s2.0-80052315340 10.1042/CS20110164
14. Drouin-Ouellet J., Cicchetti F., Inflammation and neurodegeneration: the story "retolled" Trends in Pharmacological Sciences 2012 33 10 542 551 10.1016/j.tips.2012.07.002
15. Bouchon A., Dietrich J., Colonna M., Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. The Journal of Immunology 2000 164 10 4991 4995 2-s2.0-0034657890 (Pubitemid 30305166)
16. Jiang T., Yu J. T., Zhu X. C., Tan L., TREM2 in Alzheimer's disease. Molecular Neurobiology 2013 48 1 180 185 10.1007/s12035-013-8424-8
17. Golde T. E., Streit W. J., Chakrabarty P., Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease. Alzheimer's Research & Therapy 2013 5, article 24 3 10.1186/alzrt178
18. Guerreiro R. J., Lohmann E., Bras J. M., Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurology 2013 70 78 84
19. Frank S., Burbach G. J., Bonin M., Walter M., Streit W., Bechmann I., Deller T., TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 2008 56 13 1438 1447 2-s2.0-51349085578 10.1002/glia.20710
20. Melchior B., Garcia A. E., Hsiung B.-K., Lo K. M., Doose J. M., Cameron Thrash J., Stalder A. K., Staufenbiel M., Neumann H., Carson M. J., Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: Implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro 2010 2 3, article e00037 2-s2.0-77956238665 10.1042/AN20100010
21. Paloneva J., Manninen T., Christman G., Hovanes K., Mandelin J., Adolfsson R., Bianchin M., Bird T., Miranda R., Salmaggi A., Tranebjærg L., Konttinen Y., Peltonen L., Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. The American Journal of Human Genetics 2002 71 3 656 662 2-s2.0-18544390923 10.1086/342259 (Pubitemid 34970138)
22. Singaraja R., TREM2: a new risk factor for Alzheimer's disease. Clinical Genetics 2013 83 6 525 526 10.1111/cge.12108.
23. Sessa G., Podini P., Mariani M., Meroni A., Spreafico R., Sinigaglia F., Colonna M., Panina P., Meldolesi J., Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia. European Journal of Neuroscience 2004 20 10 2617 2628 2-s2.0-9644307970 10.1111/j.1460-9568.2004.03729.x (Pubitemid 39573777)
24. Hamerman J. A., Jarjoura J. R., Humphrey M. B., Nakamura M. C., Seaman W. E., Lanier L. L., Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. The Journal of Immunology 2006 177 4 2051 2055 2-s2.0-33746875981 (Pubitemid 44200961)
25. Turnbull I. R., Gilfillan S., Cella M., Aoshi T., Miller M., Piccio L., Hernandez M., Colonna M., Cutting edge: TREM-2 attenuates macrophage activation. The Journal of Immunology 2006 177 6 3520 3524 2-s2.0-33748517428 (Pubitemid 44359882)
26. Hamerman J. A., Tchao N. K., Lowell C. A., Lanier L. L., Enhanced toll-like receptor responses in the absence of signaling adaptor DAP12. Nature Immunology 2005 6 6 579 586 2-s2.0-20644443886 10.1038/ni1204 (Pubitemid 41710728)
27. Hsieh C. L., Koike M., Spusta S. C., Niemi E. C., Yenari M., Nakamura M. C., Seaman W. E., A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. Journal of Neurochemistry 2009 109 4 1144 1156 2-s2.0-65649114773 Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement
28. Takahashi K., Prinz M., Stagi M., Chechneva O., Neumann H., TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Medicine 2007 4 4, article e124 2-s2.0-34247500821 10.1371/journal.pmed.0040124 (Pubitemid 46658770)
29. Piccio L., Buonsanti C., Mariani M., Cella M., Gilfillan S., Cross A. H., Colonna M., Panina-Bordignon P., Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. European Journal of Immunology 2007 37 5 1290 1301 2-s2.0-34250679758 10.1002/eji.200636837 (Pubitemid 46927833)
30. Guerreiro R. J., Lohmann E., Bras J. M., Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurology 2013 70 1 78 84 10.1001/jamaneurol. 2013.579
31. Paloneva J., Kestilä M., Wu J., Salminen A., Böhling T., Ruotsalainen V., Hakola P., Bakker A. B. H., Phillips J. H., Pekkarinen P., Lanier L. L., Timonen T., Peltonen L., Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nature Genetics 2000 25 3 357 361 2-s2.0-0033945864 10.1038/77153 (Pubitemid 30437329)
32. Paloneva J., Manninen T., Christman G., Hovanes K., Mandelin J., Adolfsson R., Bianchin M., Bird T., Miranda R., Salmaggi A., Tranebjærg L., Konttinen Y., Peltonen L., Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. The American Journal of Human Genetics 2002 71 3 656 662 2-s2.0-18544390923 10.1086/342259 (Pubitemid 34970138)
33. Fenoglio C., Galimberti D., Piccio L., Scalabrini D., Panina P., Buonsanti C., Venturelli E., Lovati C., Forloni G., Mariani C., Bresolin N., Scarpini E., Absence of TREM2 polymorphisms in patients with Alzheimer's disease and frontotemporal lobar degeneration. Neuroscience Letters 2007 411 2 133 137 2-s2.0-33751409163 10.1016/j.neulet.2006.10.029 (Pubitemid 44820682)
34. Rademakers R., Baker M., Nicholson A. M., Rutherford N. J., Finch N., Soto-Ortolaza A., Lash J., Wider C., Wojtas A., Dejesus-Hernandez M., Adamson J., Kouri N., Sundal C., Shuster E. A., Aasly J., MacKenzie J., Roeber S., Kretzschmar H. A., Boeve B. F., Knopman D. S., Petersen R. C., Cairns N. J., Ghetti B., Spina S., Garbern J., Tselis A. C., Uitti R., Das P., Van Gerpen J. A., Meschia J. F., Levy S., Broderick D. F., Graff-Radford N., Ross O. A., Miller B. B., Swerdlow R. H., Dickson D. W., Wszolek Z. K., Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nature Genetics 2012 44 2 200 205 2-s2.0-84856273853 10.1038/ng.1027
35. Nelson P. T., Alafuzoff I., Bigio E. H., Bouras C., Braak H., Cairns N. J., Castellani R. J., Crain B. J., Davies P., Tredici K. D., Duyckaerts C., Frosch M. P., Haroutunian V., Hof P. R., Hulette C. M., Hyman B. T., Iwatsubo T., Jellinger K. A., Jicha G. A., Kövari E., Kukull W. A., Leverenz J. B., Love S., MacKenzie I. R., Mann D. M., Masliah E., McKee A. C., Montine T. J., Morris J. C., Schneider J. A., Sonnen J. A., Thal D. R., Trojanowski J. Q., Troncoso J. C., Wisniewski T., Woltjer R. L., Beach T. G., Correlation of alzheimer disease neuropathologic changes with cognitive status: a review of the literature. Journal of Neuropathology and Experimental Neurology 2012 71 5 362 381 2-s2.0-84860215480 10.1097/NEN.0b013e31825018f7
36. Blennow K., Hampel H., CSF markers for incipient Alzheimer's disease. The Lancet Neurology 2003 2 10 605 613 2-s2.0-0141738373 10.1016/S1474-4422(03) 00530-1 (Pubitemid 37162569)
37. Hampel H., Buerger K., Zinkowski R., Teipel S. J., Goernitz A., Andreasen N., Sjoegren M., DeBernardis J., Kerkman D., Ishiguro K., Ohno H., Vanmechelen E., Vanderstichele H., McCulloch C., Möller H.-J., Davies P., Blennow K., Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Archives of General Psychiatry 2004 61 1 95 102 2-s2.0-9144257234 10.1001/archpsyc.61.1.95 (Pubitemid 38044645)
38. De Leon M. J., Desanti S., Zinkowski R., Mehta P. D., Pratico D., Segal S., Clark C., Kerkman D., Debernardis J., Li J., Lair L., Reisberg B., Tsui W., Rusinek H., MRI and CSF studies in the early diagnosis of Alzheimer's disease. Journal of Internal Medicine 2004 256 3 205 223 2-s2.0-4544306699 10.1111/j.1365-2796.2004.01381.x (Pubitemid 39222990)
39. Buerger K., Ewers M., Pirttilä T., Zinkowski R., Alafuzoff I., Teipel S. J., DeBernardis J., Kerkman D., McCulloch C., Soininen H., Hampel H., CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006 129 11 3035 3041 2-s2.0-33750589818 10.1093/brain/awl269 (Pubitemid 44684523)
40. Andersson C., Blennow K., Almkvist O., Andreasen N., Engfeldt P., Johansson S.-E., Lindau M., Eriksdotter-Jönhagen M., Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiology of Aging 2008 29 10 1466 1473 2-s2.0-49149128686 10.1016/j.neurobiolaging.2007.03.027
41. Cruchaga C., Kauwe J. S., Harari O., GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron 2013 78 256 268
42. Hashimoto C., Hudson K. L., Anderson K. V., The toll gene of drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 1988 52 2 269 279 2-s2.0-0024299087
43. Medzhitov R., Preston-Hurlburt P., Janeway C. A. Jr., A human homologue of the Drosophila toll protein signals activation of adaptive immunity. Nature 1997 388 6640 394 397 2-s2.0-0030831210 10.1038/41131 (Pubitemid 27334820)
44. Lemaitre B., Nicolas E., Michaut L., Reichhart J.-M., Hoffmann J. A., The dorsoventral regulatory gene cassette spatzle/toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996 86 6 973 983 2-s2.0-0030595339 10.1016/S0092-8674(00)80172-5 (Pubitemid 26336801)
45. Akira S., Takeda K., Functions of toll-like receptors: lessons from KO mice. Comptes Rendus 2004 327 6 581 589 2-s2.0-3242807395 10.1016/j.crvi.2004. 04.002 (Pubitemid 38979508)
46. Kawai T., Akira S., TLR signaling. Cell Death and Differentiation 2006 13 5 816 825 2-s2.0-33645960706 10.1038/sj.cdd.4401850
47. Kawai T., Akira S., Toll-like receptor and RIG-1-like receptor signaling. Annals of the New York Academy of Sciences 2008 1143 1 20 2-s2.0-56549116047 10.1196/annals.1443.020
48. Kopp E., Medzhitov R., Recognition of microbial infection by toll-like receptors. Current Opinion in Immunology 2003 15 4 396 401 2-s2.0-0042405132 10.1016/S0952-7915(03)00080-3 (Pubitemid 36930075)
49. Takeda K., Kaisho T., Akira S., Toll-like receptors. Annual Review of Immunology 2003 21 335 376 2-s2.0-0012929728 10.1146/annurev.immunol.21.120601. 141126 (Pubitemid 37174535)
50. Kawai T., Akira S., The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nature Immunology 2010 11 5 373 384 2-s2.0-77951260924 10.1038/ni.1863
51. Stewart C. R., Stuart L. M., Wilkinson K., Van Gils J. M., Deng J., Halle A., Rayner K. J., Boyer L., Zhong R., Frazier W. A., Lacy-Hulbert A., Khoury J. E., Golenbock D. T., Moore K. J., CD36 ligands promote sterile inflammation through assembly of a toll-like receptor 4 and 6 heterodimer. Nature Immunology 2010 11 2 155 161 2-s2.0-75649087741 10.1038/ni.1836
52. Frank S., Copanaki E., Burbach G. J., Müller U. C., Deller T., Differential regulation of toll-like receptor mRNAs in amyloid plaque-associated brain tissue of aged APP23 transgenic mice. Neuroscience Letters 2009 453 1 41 44 2-s2.0-60949108812 10.1016/j.neulet.2009.01.075
53. Landreth G. E., Reed-Geaghan E. G., Toll-like receptors in Alzheimer's disease. Current Topics in Microbiology and Immunology 2009 336 1 137 153 2-s2.0-75949119017 10.1007/978-3-642-00549-7-8
54. Guillot-Sestier M. V., Town T., Innate immunity in Alzheimer's disease: a complex affair. CNS & Neurological Disorders 2013 12 5 593 607
55. Wyss-Coray T., Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nature Medicine 2006 12 9 1005 1015 2-s2.0-33748471099 10.1038/nm1484
56. Medzhitov R., Janeway C. Jr., The toll receptor family and microbial recognition. Trends in Microbiology 2000 8 10 452 456 2-s2.0-0034307339 10.1016/S0966-842X(00)01845-X
57. Akira S., TLR signaling. Current Topics in Microbiology and Immunology 2006 311 1 16 (Pubitemid 47413193)
58. Hoebe K., Janssen E., Beutler B., The interface between innate and adaptive immunity. Nature Immunology 2004 5 10 971 974 2-s2.0-5444234216 10.1038/ni1004-971 (Pubitemid 41057712)
59. Pasare C., Medzhitov R., Toll-like receptors: balancing host resistance with immune tolerance. Current Opinion in Immunology 2003 15 6 677 682 2-s2.0-0242556891 10.1016/j.coi.2003.09.002 (Pubitemid 37441304)
60. Hertz C. J., Kiertscher S. M., Godowski P. J., Bouis D. A., Norgard M. V., Roth M. D., Modlin R. L., Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. The Journal of Immunology 2001 166 4 2444 2450 2-s2.0-0035865232 (Pubitemid 32173480)
61. Boonstra A., Asselin-Paturel C., Gilliet M., Crain C., Trinchieri G., Liu Y.-J., O'Garra A., Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. The Journal of Experimental Medicine 2003 197 1 101 109 2-s2.0-0037237628 10.1084/jem.20021908 (Pubitemid 36110261)
62. Poltorak A., He X., Smirnova I., Liu M.-Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., Beutler B., Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998 282 5396 2085 2088 2-s2.0-0032509295 10.1126/science.282.5396.2085 (Pubitemid 29001265)
63. Kim H. M., Park B. S., Kim J.-I., Kim S. E., Lee J., Oh S. C., Enkhbayar P., Matsushima N., Lee H., Yoo O. J., Lee J.-O., Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist eritoran. Cell 2007 130 5 906 917 2-s2.0-34548222514 10.1016/j.cell.2007.08.002 (Pubitemid 47332573)
64. Opal S. M., Esmon C. T., Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Critical Care 2003 7 1 23 38 2-s2.0-0037318946 10.1186/cc1854 (Pubitemid 36204267)
65. Aderem A., Ulevitch R. J., Toll-like receptors in the induction of the innate immune response. Nature 2000 406 6797 782 787 2-s2.0-0034680145 10.1038/35021228
66. Yu L., Wang L., Li M., Zhong J., Wang Z., Chen S., Expression of toll-like receptor 4 is down-regulated during progression of cervical neoplasia. Cancer Immunology, Immunotherapy 2010 59 7 1021 1028 2-s2.0-77953055482 10.1007/s00262-010-0825-1
67. Lagos D., Vart R. J., Gratrix F., Westrop S. J., Emuss V., Wong P.-P., Robey R., Imami N., Bower M., Gotch F., Boshoff C., Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus. Cell Host and Microbe 2008 4 5 470 483 2-s2.0-55249114624 10.1016/j.chom.2008.09.012
68. Kelly M. G., Alvero A. B., Chen R., Silasi D.-A., Abrahams V. M., Chan S., Visintin I., Rutherford T., Mor G., TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Research 2006 66 7 3859 3868 2-s2.0-33645727988 10.1158/0008-5472.CAN-05-3948
69. He W., Liu Q., Wang L., Chen W., Li N., Cao X., TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Molecular Immunology 2007 44 11 2850 2859 2-s2.0-33947179887 10.1016/j.molimm.2007.01.022 (Pubitemid 46412506)
70. Kilic U., Kilic E., Matter C. M., Bassetti C. L., Hermann D. M., TLR-4 deficiency protects against focal cerebral ischemia and axotomy-induced neurodegeneration. Neurobiology of Disease 2008 31 1 33 40 2-s2.0-45049087782 10.1016/j.nbd.2008.03.002
71. Krieg A. M., CpG DNA: a pathogenic factor in systemic lupus erythematosus? Journal of Clinical Immunology 1995 15 6 284 292 2-s2.0-0028824955 10.1007/BF01541318
72. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S., A toll-like receptor recognizes bacterial DNA. Nature 2000 408 6813 740 745 2-s2.0-0034619794 10.1038/35047123 (Pubitemid 32015992)
73. Ahmad-Nejad P., Hacker H., Rutz M., Bauer S., Vabulas R. M., Wagner H., Bacterial CpG-DNA and lipopolysaccharides activate toll-like receptors at distinct cellular compartments. European Journal of Immunology 2002 32 1958 1968 (Pubitemid 34814552)
74. Letiembre M., Hao W., Liu Y., Walter S., Mihaljevic I., Rivest S., Hartmann T., Fassbender K., Innate immune receptor expression in normal brain aging. Neuroscience 2007 146 1 248 254 2-s2.0-34247471687 10.1016/j. neuroscience.2007.01.004 (Pubitemid 46661885)
75. Aravalli R. N., Hu S., Lokensgard J. R., Toll-like receptor 2 signaling is a mediator of apoptosis in herpes simplex virus-infected microglia. Journal of Neuroinflammation 2007 4, article 11 2-s2.0-34248630818 10.1186/1742-2094-4- 11 (Pubitemid 46767385)
76. Jack C. S., Arbour N., Manusow J., Montgrain V., Blain M., McCrea E., Shapiro A., Antel J. P., TLR signaling tailors innate immune responses in human microglia and astrocytes. The Journal of Immunology 2005 175 7 4320 4330 2-s2.0-25444498280 (Pubitemid 41361966)
77. Ito H., Hamerman J. A., TREM-2, triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells. European Journal of Immunology 2012 42 1 176 185 2-s2.0-84855221945 10.1002/eji.201141679
78. Tahara K., Kim H.-D., Jin J.-J., Maxwell J. A., Li L., Fukuchi K.-I., Role of toll-like receptor signalling in A β uptake and clearance. Brain 2006 129 11 3006 3019 2-s2.0-33750576993 10.1093/brain/awl249 (Pubitemid 44684521)
79. Cameron B., Landreth G. E., Inflammation, microglia, and alzheimer's disease. Neurobiology of Disease 2010 37 3 503 509 2-s2.0-75949127362 10.1016/j.nbd.2009.10.006
80. Liu Y., Walter S., Stagi M., Cherny D., Letiembre M., Schulz-Schaeffer W., Heine H., Penke B., Neumann H., Fassbender K., LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain 2005 128 8 1778 1789 2-s2.0-23444448277 10.1093/brain/awh531 (Pubitemid 41373649)
81. Fassbender K., Walter S., Kühl S., Landmann R., Ishii K., Bertsch T., Stalder A. K., Muehlhauser F., Liu Y., Ulmer A. J., Rivest S., Lentschat A., Gulbins E., Jucker M., Staufenbiel M., Brechtel K., Walter J., Multhaup G., Penke B., Adachi Y., Hartmann T., Beyreuther K., The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB Journal 2004 18 1 203 205 2-s2.0-1342332161
82. Walter S., Letiembre M., Liu Y., Heine H., Penke B., Hao W., Bode B., Manietta N., Walter J., Schulz-Schüffer W., Faßbender K., Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cellular Physiology and Biochemistry 2007 20 6 947 956 2-s2.0-35848963223 10.1159/000110455 (Pubitemid 350059737)
83. Jin J.-J., Kim H.-D., Maxwell J. A., Li L., Fukuchi K.-I., Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. Journal of Neuroinflammation 2008 5, article 23 2-s2.0-45849105153 10.1186/1742-2094-5-23 (Pubitemid 351877817)
84. Reed-Geaghan E. G., Savage J. C., Hise A. G., Landreth G. E., CD14 and toll-like receptors 2 and 4 are required for fibrillar A β -stimulated microglial activation. Journal of Neuroscience 2009 29 38 11982 11992 2-s2.0-70349323417 10.1523/JNEUROSCI.3158-09.2009
85. Michaud J. P., Halle M., Lampron A., Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology. Proceedings of the National Academy of Sciences of the United States of America 2013 110 5 1941 1946 10.1073/pnas.1215165110
86. Rolls A., Shechter R., London A., Ziv Y., Ronen A., Levy R., Schwartz M., Toll-like receptors modulate adult hippocampal neurogenesis. Nature Cell Biology 2007 9 9 1081 1088 2-s2.0-34548358816 10.1038/ncb1629 (Pubitemid 47338146)
87. Doi Y., Mizuno T., Maki Y., Jin S., Mizoguchi H., Ikeyama M., Doi M., Michikawa M., Takeuchi H., Suzumura A., Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid β neurotoxicity in in vitro and in vivo models of Alzheimer's disease. American Journal of Pathology 2009 175 5 2121 2132 2-s2.0-73649137143 10.2353/ajpath.2009.090418
88. Scholtzova H., Kascsak R. J., Bates K. A., Boutajangout A., Kerr D. J., Meeker H. C., Mehta P. D., Spinner D. S., Wisniewski T., Induction of toll-like receptor 9 signaling as a method for ameliorating alzheimer's disease-related pathology. Journal of Neuroscience 2009 29 6 1846 1854 2-s2.0-60849137841 10.1523/JNEUROSCI.5715-08.2009
89. Spinner D. S., Kascsak R. B., LaFauci G., Meeker H. C., Ye X., Flory M. J., Kim J. I., Schuller-Levis G. B., Levis W. R., Wisniewski T., Carp R. I., Kascsak R. J., CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils. Journal of Leukocyte Biology 2007 81 6 1374 1385 2-s2.0-34249690678 10.1189/jlb.1106665 (Pubitemid 46827960)
90. Krieg A. M., Therapeutic potential of toll-like receptor 9 activation. Nature Reviews Drug Discovery 2006 5 6 471 484 2-s2.0-33745946911 10.1038/nrd2059 (Pubitemid 44136959)
91. Bodera P., Stankiewicz W., Kocik J., Synthetic immunostimulatory oligonucleotides in experimental and clinical practice. Pharmacological Reports 2012 64 1003 1010
92. Scholtzova H., Goni F., Pan J., Sun Y., Mehta P., Wisniewski T., Innate immunity stimulation as a novel therapeutic approach in Alzheimer's disease. Alzheimer's & Dementia 2012 8 4 392 10.1016/j.jalz.2012.05.1078
93. Wisniewski H. M., Wegiel J., Wang K. C., Lach B., Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer's disease. Acta Neuropathologica 1992 84 2 117 127 2-s2.0-0026685656 10.1007/BF00311383
94. Frackowiak J., Wisniewski H. M., Wegiel J., Merz G. S., Iqbal K., Wang K. C., Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce β -amyloid fibrils. Acta Neuropathologica 1992 84 3 225 233 2-s2.0-0026783591
95. Wisniewski H. M., Wegiel J., The role of microglia in amyloid fibril formation. Neuropathology and Applied Neurobiology 1994 20 2 192 194 2-s2.0-0028269039 (Pubitemid 24123560)
96. Shi H., Belbin O., Medway C., Brown K., Kalsheker N., Carrasquillo M., Proitsi P., Powell J., Lovestone S., Goate A., Younkin S., Passmore P., Morgan K., Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS). Neurobiology of Aging 2012 33 8 1849.e5 1849.e18 2-s2.0-84858713634 10.1016/j.neurobiolaging.2012.02.014